$19.11
4.11% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US67080M1036
Symbol
NRIX
Sector
Industry

Nurix Therapeutics Inc Stock price

$19.11
-2.12 9.99% 1M
-1.63 7.86% 6M
+8.79 85.17% YTD
+9.36 96.00% 1Y
-11.24 37.03% 3Y
+0.10 0.53% 5Y
+0.10 0.53% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.82 4.11%
ISIN
US67080M1036
Symbol
NRIX
Sector
Industry

Key metrics

Market capitalization $1.35b
Enterprise Value $932.77m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 16.53
P/S ratio (TTM) P/S ratio 23.99
P/B ratio (TTM) P/B ratio 3.40
Revenue growth (TTM) Revenue growth -17.76%
Revenue (TTM) Revenue $56.42m
EBIT (operating result TTM) EBIT $-193.70m
Free Cash Flow (TTM) Free Cash Flow $-106.90m
Cash position $448.05m
EPS (TTM) EPS $-2.91
P/E forward negative
P/S forward 24.79
EV/Sales forward 17.08
Short interest 14.16%
Show more

Is Nurix Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Nurix Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Nurix Therapeutics Inc forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Nurix Therapeutics Inc forecast:

Buy
94%
Hold
6%

Financial data from Nurix Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Aug '24
+/-
%
56 56
18% 18%
100%
- Direct Costs 16 16
23% 23%
28%
41 41
27% 27%
72%
- Selling and Administrative Expenses 23 23
0% 0%
41%
- Research and Development Expense 195 195
10% 10%
346%
-178 -178
22% 22%
-315%
- Depreciation and Amortization 16 16
23% 23%
28%
EBIT (Operating Income) EBIT -194 -194
22% 22%
-343%
Net Profit -177 -177
19% 19%
-314%

In millions USD.

Don't miss a Thing! We will send you all news about Nurix Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nurix Therapeutics Inc Stock News

Neutral
GlobeNewsWire
10 days ago
Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom's Macroglobulinemia Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom's Macroglobulinemia
Neutral
GlobeNewsWire
19 days ago
Durable responses are rapid and deepen on treatment as demonstrated by an initial 75.5% Objective Response Rate which increased to 84.2% in patients with at least two disease assessments
Neutral
GlobeNewsWire
27 days ago
SAN FRANCISCO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the company will host a live webcast to review new clinical data from the ongoing Phase 1a/1b clinical trial of its Bruton's tyrosin...
More Nurix Therapeutics Inc News

Company Profile

Nurix Therapeutics, Inc. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Head office United States
CEO Arthur Sands
Employees 284
Founded 2009
Website www.nurixtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today